Arcutis Biotherapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2017 - 2019
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2017 - 2019
Operating Revenue	208.82	166.54	29.19	3.69	-	-	Upgrade
Other Revenue	4	30	30.42	-	-	-	Upgrade
Revenue	212.82	196.54	59.61	3.69	-	-	Upgrade
Revenue Growth (YoY)	100.03%	229.73%	1517.09%	-	-	-	Upgrade
Cost of Revenue	24.7	19.13	4.99	0.75	-	-	Upgrade
Gross Profit	188.12	177.41	54.62	2.93	-	-	Upgrade
Selling, General & Admin	238.6	229.39	185.15	122.12	60.97	21.34	Upgrade
Research & Development	70.82	76.42	110.58	182.44	145.56	115.31	Upgrade
Operating Expenses	309.42	305.81	295.72	304.56	206.53	136.65	Upgrade
Operating Income	-121.3	-128.4	-241.1	-301.63	-206.53	-136.65	Upgrade
Interest Expense	-22.67	-27.17	-29.71	-15.65	-	-	Upgrade
Interest & Investment Income	15.16	16.17	11.79	5.82	0.17	0.97	Upgrade
Other Non Operating Income (Expenses)	-0.3	-	-	-	-	-	Upgrade
Pretax Income	-129.12	-139.39	-259.03	-311.46	-206.36	-135.68	Upgrade
Income Tax Expense	0.6	0.65	3.11	-	-	-	Upgrade
Net Income	-129.72	-140.04	-262.14	-311.46	-206.36	-135.68	Upgrade
Net Income to Common	-129.72	-140.04	-262.14	-311.46	-206.36	-135.68	Upgrade
Shares Outstanding (Basic)	125	121	69	55	49	36	Upgrade
Shares Outstanding (Diluted)	125	121	69	55	49	36	Upgrade
Shares Change (YoY)	52.50%	74.53%	25.94%	11.39%	38.52%	1835.11%	Upgrade
EPS (Basic)	-1.04	-1.16	-3.78	-5.66	-4.18	-3.80	Upgrade
EPS (Diluted)	-1.04	-1.16	-3.78	-5.66	-4.18	-3.80	Upgrade
Free Cash Flow	-111.69	-112.3	-247.49	-258.05	-175.62	-113.35	Upgrade
Free Cash Flow Per Share	-0.90	-0.93	-3.57	-4.69	-3.56	-3.18	Upgrade
Gross Margin	88.39%	90.27%	91.63%	79.54%	-	-	Upgrade
Operating Margin	-57.00%	-65.33%	-404.49%	-8183.04%	-	-	Upgrade
Profit Margin	-60.95%	-71.25%	-439.79%	-8449.76%	-	-	Upgrade
Free Cash Flow Margin	-52.48%	-57.14%	-415.20%	-7000.76%	-	-	Upgrade
EBITDA	-115.93	-125.8	-239.58	-300.69	-206.08	-136.52	Upgrade
EBITDA Margin	-54.47%	-64.01%	-	-	-	-	Upgrade
D&A For EBITDA	5.37	2.6	1.52	0.93	0.45	0.12	Upgrade
EBIT	-121.3	-128.4	-241.1	-301.63	-206.53	-136.65	Upgrade
EBIT Margin	-57.00%	-65.33%	-	-	-	-	Upgrade
Revenue as Reported	212.82	196.54	59.61	3.69	-	-	Upgrade

Updated Feb 25, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q